8 results match your criteria: "Hjertecenteret[Affiliation]"
Ugeskr Laeger
September 2023
Afdeling for Hjertesygdomme, Afsnit for Lunge Transplantation, Hjertecenteret, Københavns Universitetshospital - Rigshospitalet.
Donation after circulatory death (DCD) is practiced in several countries to increase the number of organs for transplantation. This review summarises the key points in a new protocol which will introduce controlled DCD in Denmark as an option in seriously ill patients, in whom death is inevitable and the criteria for brain death is not met. It includes a no touch period of five minutes following circulatory arrest.
View Article and Find Full Text PDFUgeskr Laeger
June 2022
Afdeling for Hjertesygdomme, Hjertecenteret, Københavns Universitetshospital - Rigshospitalet.
Inflammation is increasingly recognised as a causal factor in the development and progression of cardiovascular disease. With the introduction of immune checkpoint inhibitors in oncology and the ongoing COVID-19 pandemic the role of the immune system in myocardial inflammation (myocarditis) and subsequent inflammatory cardiomyopathy has once again regained attention. In this review, we want to bring myocardial inflammation to the clinician's attention and provide up-to-date knowledge on its diagnostic workup, prognostication, and current management recommendations.
View Article and Find Full Text PDFUgeskr Laeger
February 2015
Kardiologisk Laboratorium 2014, Hjertecenteret, Rigshospitalet, Blegdamsvej 9, 2100 København Ø.
The present Cochrane review included 23 studies randomized placebo-controlled clinical trials with a total of 1,255 patients. The effect of autologous cell therapy versus placebo was examined on left ventricular ejection fraction (LVEF), adverse effects and mortality in patients with chronic ischaemic heart disease. Patients treated with cell therapy had improved LVEF and functional status compared to patients who received placebo.
View Article and Find Full Text PDFUgeskr Laeger
July 2014
Hjertecenteret, Afsnit for Lungetransplantation, Rigshospitalet, Blegdamsvej 9, 2100 København Ø. E-mail:
Introduction of bronchoscopic lung volume reduction as a treatment for severe emphysema has been defined as an area of development by The Danish Health and Medicines Authority. We here present the rationale for treatment, in- and exclusion criteria, and ultimately the organization for assessment, treatment and follow-up in Denmark. The treatment aim is to lower dyspnoea.
View Article and Find Full Text PDFUgeskr Laeger
May 2010
Hjertecenteret og Patologiafdelingen, Rigshospitalet, DK-2100 København Ø, Denmark.
We discuss the first Danish case in which a left ventricular assist device (HeartMate 2) could be explanted after 13 months of support due to cardiac recovery in a young patient who presented with severe dilated cardiomyopathy during pregnancy. Aggressive medical treatment with angiotensin converting enzyme inhibitor, beta blocker and aldosterone antagonist was used, and the patient remained stable without circulatory support several months after device removal.
View Article and Find Full Text PDFUgeskr Laeger
June 2009
Rigshospitalet, Hjertecenteret, Hjertemedicinsk Klinik B, København Ø.
Within the latest ten years research in left ventricular hypertrophy as cardiac target organ damage has uncovered its prognostic importance, and studies indicate that treatment with angiotensin II receptor blockade is most effective in reducing left ventricular hypertrophy. In addition, reduction of left ventricular mass is associated with substantial and significant reduction of cardiovascular morbidity and mortality. Hypertension is strongly associated with increased risk of subsequent heart failure.
View Article and Find Full Text PDFUgeskr Laeger
November 2004
H:S Rigshospitalet, Hjertecenteret, Laboratorium for Molekylaer Kardiologi og Medicinsk Afdeling B, København.
Cardiovasc Res
October 2002
Laboratoriet for Molekylaer Kardiologi and Hjertecenteret H:S, Rigshospitalet. 20, Juliane Mariesvej., Copenhagen Ø, Denmark.
Objective: Cardiac hypertrophy is induced by a number of stimuli and can lead to cardiomyopathy and heart failure. Present knowledge suggests that cell-cycle regulatory proteins take part in hypertrophy. We have investigated if the D-type cyclins are involved in cardiac hypertrophy.
View Article and Find Full Text PDF